Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

NCT06364800 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: γδ T cells
DRUG: PD-1 monoclonal antibody
DRUG: targeted drugs

Sponsor

Beijing 302 Hospital

Collaborators

[object Object]
[object Object]